Cytokine and chemokine tear levels in patients with uveitis

Carreño, Ester; Portero, Alejandro; Herreras, José M.; Garcı́a-Vázquez, Carmen; Whitcup, Scott M.; Stern, Michael E.; Calonge, Margarita; Salamanca, Andrés Bordalí

doi:10.1111/aos.13292

Cited by 46 publications

(41 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…If tears can reflect uveitis activity, similar to AqH, it may be a promising bios- pecimen for uveitis biomarker studies. Carreon and col- leagues report differences in the cytokine and chemokine tear profiles of adult uveitis patients compared to healthy controls and differences based on uveitis anatomic classification, wherein patients with anterior and panuveitis had increased concen- trations compared to controls and intermediate and posterior uveitis [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

“…Analysis of tears may also be a non-invasive approach to assess biomarkers of uveitis, in order to identify children with JIA who are most susceptible to uveitis, and it may be reflective of intraocular pathology. Differences in the levels of cytokines and chemokines have been reported in the tears of adults with uveitis compared to healthy subjects [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Discovery of tear biomarkers in children with chronic non-infectious anterior uveitis: a pilot study

Angeles‐Han

Yeh

Patel

et al. 2018

J Ophthal Inflamm Infect

View full text Add to dashboard Cite

BackgroundBiomarkers in easily obtained specimens that accurately predict uveitis in children with juvenile idiopathic arthritis (JIA) are needed. Aqueous humor has been studied for biomarkers, but is not routinely available. We evaluated tears from children with chronic anterior uveitis (CAU) for biomarkers reported in aqueous humor.In this pilot study, we used Schirmer strips to collect tears from seven children (nine eyes); three children had JIA- associated uveitis (JIA-U) and four had idiopathic disease (I-CAU). Liquid chromatography-tandem mass spectrometry was used to identify and quantify tear proteins. The Mann-Whitney U test identified differential tear protein expression between children with JIA-U and those with I-CAU.ResultsS100A9, LAP3, TTR, MIF, sCD14, S100A8, and SAA1 were detected in tears of all children; the same cytokines have been reported in aqueous humor of children with JIA-U. Tears from children with JIA-U had higher expression of proteins associated with inflammatory arthritis (SEMA3G, TIMP1, HEXB, ERN1, and SAA1) than tears from those with I-CAU. In addition, we found higher expression of sCD14, S100A8, and SAA1, but lower expression of S100A9, LAP3, TTR, and MIF, in tears from children with JIA-U compared to tears from those with I-CAU.ConclusionsTears contain similar cytokine profiles to aqueous humor in children with CAU and may be a clinically useful source of disease biomarkers. Tears from children with JIA-U also contain cytokines associated with inflammatory arthritis; furthermore, differential expression of other tear proteins as well may provide clues to intrinsic differences between JIA-U and I-CAU, despite their similar clinical phenotypes.Electronic supplementary materialThe online version of this article (10.1186/s12348-018-0156-5) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Discovery of tear biomarkers in children with chronic non-infectious anterior uveitis: a pilot study

Angeles‐Han

Yeh

Patel

et al. 2018

J Ophthal Inflamm Infect

View full text Add to dashboard Cite

show abstract

“…IL-1β signals through the IL-1 receptor (IL-1R) to produce its inflammatory effects such as differentiation and expansion of antigen-specific T cells, cell maturation, and induction of acutephase reaction [134]. This cytokine signaling is known to play a role in autoimmune diseases as demonstrated clinically with significantly elevated levels of IL-1β in biological samples including tears of uveitis patients compared to healthy controls [135]. Also, high levels of this cytokine are implicated in some systemic autoimmune diseases including those associated with uveitis [131].…”

Section: Il-1 Inhibitorsmentioning

confidence: 99%

Biological Therapies that Target Inflammatory Cytokines to Treat Uveitis

Reddy¹,

Muhammad²,

Lee³

2019

Advances in the Diagnosis and Management of Uveitis

View full text Add to dashboard Cite

Uveitis is a leading cause of blindness that presents a considerable challenge given that our understanding of the mechanisms of disease is still evolving. Both innate and adaptive immunity play a role in disease and mediators of these responses can serve as therapeutic targets. TNF-α and IL-1β inflammatory cytokines are central mediators of immunity and are involved in the dysregulated inflammatory response during uveitis. Because toxicity limits the use of steroids and other steroid-sparing agents, biologics that target a specific cell type or pathway are being explored for the treatment of autoimmune uveitis. This chapter begins with a broad overview of the aberrant immune response resulting in uveitis, and highlights key mediators such as TNF-α, IL-1β, IL-6, and IL-17 and their potential use as therapeutic targets. Most biological agents discussed in this review have not been FDAapproved for uveitis. However, favorable outcomes in early trials and FDA approval of these drugs for the treatment of other autoimmune diseases associated with uveitis support the potential for these biological agents in the management of uveitis. This review aims to provide an updated report on the efficacy of biologics that target TNF-α, IL-1β, IL-6, and IL-17 for the treatment of autoimmune uveitis.

show abstract

“…Different cytokines and chemokine have been involved in the pathogenesis of uveitis and have been shown to be elevated in patients with uveitis (Carreño et al 2016). Tumour necrosis factor (TNF) has been the leading target for NIU biologic treatment (Nakamura et al 1994;Dick et al 2004;Caspi 2010;Srivastava et al 2010;Cordero-Coma & Sobrin 2015).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of intravitreal anti‐tumour necrosis factor drugs in adults with non‐infectious uveitis – a systematic review

Leal

Rodrigues

Sousa

et al. 2018

Acta Ophthalmologica

Self Cite

View full text Add to dashboard Cite

Anti-tumour necrosis factor (TNF) drugs have been extensively used in non-infectious uveitis (NIU), when corticosteroids or conventional immunosuppressive drugs cannot adequately control inflammation or intolerable side-effects occur. However, systemic anti-TNF therapies are also associated with a myriad of side-effects. Therefore, intravitreal administration of anti-TNF biologics has been employed to minimize patient morbidity and systemic adverse effects, while maintaining therapeutic effectivity. We undertook a systematic review to determine evidence of efficacy and safety of intravitreal administration of anti-TNF drugs in adults with NIU. We conducted this systematic review according to the PRISMA guidelines. The protocol was registered with PROSPERO (CRD42016041946). We searched CENTRAL, MEDLINE and EMBASE, from inception to April 2017, as well as clinical trial registries and grey literature. The qualitative analysis included all studies of adult patients with a diagnosis of NIU and who received intravitreal anti-TNF drugs with a 4-week minimum follow-up. A total of 4840 references were considered for title and abstract screening. Seven full texts were screened, and five studies were considered for analysis. All studies were open-label, single-centre, prospective, non-randomized, interventional case series with a follow-up between 4 and 26 weeks, employing either adalimumab in two studies and infliximab in three. Three studies showed a treatment effect of anti-TNF intravitreal injections, while one study revealed short-term improvement and one study revealed no efficacy of anti-TNF intravitreal therapy. None of the studies reported ocular adverse effects but only two studies included electrophysiological assessment in the safety analysis and no study assessed systemic human anti-drug antibodies. The available evidence is not sufficiently robust to conclude about the clinical effectivity of intravitreal anti-TNF in NIU and so no recommendation can be made. In conclusion, intravitreal injection of anti-TNF antibodies remains a possible treatment option to be explored through robust clinical investigation.

show abstract

Cytokine and chemokine tear levels in patients with uveitis

Abstract: There were significant differences in the levels of several cytokines and chemokines in tears of patients with uveitis compared with healthy subjects. These results can help understand the underlying pathophysiology of the uveitis and could potentially aid in diagnosis.

Cited by 46 publications

References 50 publications

Discovery of tear biomarkers in children with chronic non-infectious anterior uveitis: a pilot study

Discovery of tear biomarkers in children with chronic non-infectious anterior uveitis: a pilot study

Biological Therapies that Target Inflammatory Cytokines to Treat Uveitis

Efficacy and safety of intravitreal anti‐tumour necrosis factor drugs in adults with non‐infectious uveitis – a systematic review

Contact Info

Product

Resources

About